Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Insulin resistance (IR), considered a hallmark of diabetes at the cellular level, is implicated in pre-diabetes, results in type 2 diabetes, and negatively affects mitochondrial function. Diabetes is increasingly associated with enhanced risk of developing Parkinson’s disease (PD); however, the underlying mechanism remains unclear. This study investigated the probable culpability of IR in the pathogenesis of PD. Methods: Using MitoPark mice in vivo models, diabetes was induced by a high-fat diet in the in vivo models, and IR was induced by protracted pulse-stimulation with 100 nM insulin treatment of neuronal cells, in vitro to determine the molecular mechanism(s) underlying altered cellular functions in PD, including mitochondrial dysfunction and α-synuclein (SNCA) aberrant expression. Findings: We observed increased SNCA expression in the dopaminergic (DA) neurons of both the wild-type and diabetic MitoPark mice, coupled with enhanced degeneration of DA neurons in the diabetic MitoPark mice. Ex vivo, in differentiated human DA neurons, IR was associated with increased SNCA and reactive oxygen species (ROS) levels, as well as mitochondrial depolarization. Moreover, we demonstrated concomitant hyperactivation of polo-like kinase-2 (PLK2), and upregulated p-SNCA (Ser129) and proteinase K-resistant SNCA proteins level in IR SH-SY5Y cells, however the inhibition of PLK2 reversed IR-related increases in phosphorylated and total SNCA. Similarly, the overexpression of peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC)-1α suppressed ROS production, repressed PLK2 hyperactivity, and resulted in downregulation of total and Ser129-phosphorylated SNCA in the IR SH-SY5Y cells. Conclusions: These findings demonstrate that IR-associated diabetes promotes the development and progression of PD through PLK2-mediated mitochondrial dysfunction, upregulated ROS production, and enhanced SNCA signaling, suggesting the therapeutic targetability of PLK2 and/or SNCA as potential novel disease-modifying strategies in patients with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, insulin resistance affects the clearance of Aβ, the hyperphosphorylation of tau, and glucose metabolism and enhances the aberrant expression of α-syn.356,357”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [357]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: A shared comparison of diabetes mellitus and neurodegenerative disorders
Morsi, M., Maher, A., Aboelmagd, O., Johar, D., & Bernstein, L. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26261 · Cited by 49
RetractedDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · cited 1×
“Impaired cellular response to insulin, known as insulin resistance (IR), is a hallmark of type 2 diabetes and contributes to the systemic downstream detrimental effects of diabetes [2].”
BackgroundRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Copps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 2×
“Mechanistically, since increased p85α expression and IRS1 serine phosphorylation are essential for the induction of clinically-apparent IR [32], we demonstrated significant increase in the p-IRS1/IRS1 ratio (123%, p < 0.”
BackgroundPARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953 · cited 1×
“In addition, deregulated parkin (PRKN) expression and/or activity is pathognomonic to PD, however, parkin-interacting substrate (PARIS/ZNF746), a Krüppel-associated box-zinc finger protein (KRAB-ZFP) that accumulates in models of parkin (PRKN) inactivation and in the brain of patients with PD, has been shown to repres…”
BackgroundQuantitative Analysis of Histological Staining and Fluorescence Using ImageJ
Jensen, E. C. (2013) · The Anatomical Record · doi:10.1002/ar.22641 · Cited by 941
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“Furthermore, several anti-glycemic agents, including exenatide, a glucagon-like peptide analogue, have exerted a disease-modifying effect on PD; exenatide is presently in phase III clinical trial as a neuroprotective drug for patients with PD [18,19].”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Cited by
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“In diabetic mice models and an ex vivo experimental design, insulin resistance was associated with increased α -synuclein expression (Hong et al., 2020).”
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
Pignalosa, F. C., Desiderio, A., Mirra, P., Nigro, C., Perruolo, G., Ulianich, L., Formisano, P., Bèguinot, F., Miele, C., Napoli, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212366 · Cited by 136
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
Labandeira, C. M., Bau, A. F., Ron, D. A., Álvarez, E., Alba, P. V., Garma, J. L., & Rodriguez-Perez, A. I. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332122 · Cited by 104
Glucose metabolism impairment in Parkinson’s disease
Dai, C., Tan, C., Zhao, L., Liang, Y., Liu, G., Liu, H., Zhong, Y., Liu, Z., Mo, L., Liu, X., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110672 · Cited by 99
Cheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
Self-citationHassan, A. T., Kandel, R. S., Mishra, R., Gautam, J., Alaref, A. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9853 · Cited by 79
Aune, D., Schlesinger, S., Mahamat‐Saleh, Y., Zheng, B., Udeh‐Momoh, C. T., & Middleton, L. T. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00970-0 · Cited by 83
Wang, X.-W., Yuan, L.-J., Yang, Y., Zhang, M., & Chen, W. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00071.2020 · Cited by 74
Álvarez, M. M., Cano-Herrera, G., Martínez, M. F. O., Gonzales-Portillo, J. V., Monroy, G. R., Pérez, R. M., Torres-Ríos, J. A., van Tienhoven, X. A., Bernot, E. M. G., Salazar, F. E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137183 · Cited by 88
Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses
Komici, K., Femminella, G. D., Bencivenga, L., Rengo, G., & Pagano, G. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212725 · Cited by 73
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 89
Ruiz-Pozo, V. A., Tamayo-Trujillo, R., Cadena-Ullauri, S., Frias-Toral, E., Guevara-Ramírez, P., Paz-Cruz, E., Chapela, S., Montalván, M., Morales-López, T., Simancas-Racines, D., et al. (2023) · Nutrients · doi:10.3390/nu15163585 · Cited by 63
Kooshki, L., Zarneshan, S. N., Fakhri, S., Moradi, S. Z., & Echeverría, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154686 · Cited by 69
Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 68
Standpoints in mitochondrial dysfunction: Underlying mechanisms in search of therapeutic strategies
Videla, L. A., Mariman, A. P., Ramos, B., Silva, M. J., & del Campo, A. (2022) · Mitochondrion · doi:10.1016/j.mito.2021.12.006 · Cited by 55
Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving
Haas, J., Berg, D., Bosy‐Westphal, A., & Schaeffer, E. (2022) · Nutrients · doi:10.3390/nu14153240 · Cited by 57
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Armstrong, M. J., Svensson, M., Virnig, B. A., et al. (2024) · Movement Disorders · doi:10.1002/mds.29992 · Cited by 47
Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance
Al-Sayyar, A., Hammad, M. M., Williams, M. R., Al‐Onaizi, M., Abubaker, J. A., & Alzaïd, F. (2023) · Metabolites · doi:10.3390/metabo13030384 · Cited by 48
Probiotics treatment for Parkinson disease: a systematic review and meta-analysis of clinical trials
Hong, C., Chen, J., & Huang, T. (2022) · Aging · doi:10.18632/aging.204266 · Cited by 45
Self-citationChou, S., Chan, L., Chung, C., Chiu, J.-Y., Hsieh, Y., & Hong, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564641 · Cited by 38
Self-citationNassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 35
Potential roles of branched-chain amino acids in neurodegeneration
Yoo, H.-S., Shanmugalingam, U., & Smith, P. D. (2022) · Nutrition · doi:10.1016/j.nut.2022.111762 · Cited by 42
Polo-Like Kinase 2: From Principle to Practice
Zhang, C., Ni, C., & Lu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956225 · Cited by 35
Type 2 diabetes mellitus and neurodegenerative disorders: The mitochondrial connection
Baduini, I. R., Castro-Vildosola, J., Kavehmoghaddam, S., Kiliç, F., Nadeem, S. A., Nizama, J. J., Rowand, M. A., Annapureddy, D., Bryan, C.-A., Do, L. H., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107439 · Cited by 33
Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model
Beckstead, M. J., & Howell, R. D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113707 · Cited by 36
Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
Bi, M., Du, X., Xiao, X., Dai, Y., Jiao, Q., Chen, X., Zhang, L., & Jiang, H. F. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102167 · Cited by 31
González, L. F., Bevilacqua, L. E., & Naves, R. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122055 · Cited by 32
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Piątkowska‐Chmiel, I., Herbet, M., Gawrońska‐Grzywacz, M., Pawłowski, K., Ostrowska-Leśko, M., & Dudka, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06341-7 · Cited by 35
Alberry, B., & Silveira, P. P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105350 · Cited by 30
The retina-brain axis and diabetic retinopathy
Ebrahimi, M., Thompson, P. M., Lauer, A. K., Sivaprasad, S., & Perry, G. L. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231172229 · Cited by 27
Amo-Aparicio, J., Dinarello, C. A., & Lopez-Vales, R. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.391330 · Cited by 25
Juárez‐Flores, D. L., Ezquerra, M., González‐Casacuberta, I., Ormazábal, A., Morén, C., TOLOSA, E. S., Fucho, R., Guitart‐Mampel, M., Casado, M., Valldeoriola, F., et al. (2020) · Antioxidants · doi:10.3390/antiox9111063 · Cited by 24
Dysmetabolism and Neurodegeneration: Trick or Treat?
Capucho, A. M., Chegão, A., Martins, F. O., Miranda, H. V., & Conde, S. V. (2022) · Nutrients · doi:10.3390/nu14071425 · Cited by 28
Sandeep, X. X. X. X., Ahmad, M. H., Rani, L., & Mondal, A. C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02867-7 · Cited by 25
Insulin Resistance Is a Modifying Factor for Parkinson's Disease
Žagare, A., Hemedan, A. A., Serra-Almeida, C., Frangenberg, D., Gomez‐Giro, G., Antony, P. M. A., Halder, R., Krüger, R., Glaab, E., Ostaszewski, M., et al. (2024) · Movement Disorders · doi:10.1002/mds.30039 · Cited by 28
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp, K. O., Glotfelty, E. J., Li, Y., Lahiri, D. K., & Greig, N. H. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102343 · Cited by 24
Aging and “Age-Related” Diseases - What Is the Relation?
Kopp, W. (2024) · Aging and Disease · doi:10.14336/ad.2024.0570 · Cited by 52
The Role of Intermittent Fasting in Parkinson's Disease
Neth, B. J., Bauer, B. A., Benarroch, E. E., & Savica, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.682184 · Cited by 24
Liu, S., Liu, T., Li, J., Hong, J., Moosavi‐Movahedi, A. A., & Wei, J. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-024-01342-8 · Cited by 24
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease
Luthra, N., Mehta, N., Munoz, M. J., Fantuzzi, G., Lamotte, G. J., Haus, J. M., McFarland, N. R., Tansey, M. G., González-Latapí, P., Caraveo, G., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01042-8 · Cited by 28
Faizan, M., Sarkar, A., & Singh, M. P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101727 · Cited by 25
Helal, M. M., AbouShawareb, H., Abbas, O., Haddad, R., Zain, Y. E., Osman, A. S. A., & Hassan, A. K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01888-1 · Cited by 23
Bantounou, M. A., Shoaib, K., Mazzoleni, A., Modalavalasa, H., Kumar, N. S., & Philip, S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100158 · Cited by 23
A review of Plks: Thinking outside the (polo) box
Korns, J., Liu, X., & Takiar, V. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23388 · Cited by 17
Advancements and future directions in research of the roles of insulin in amyloid diseases
Miller, Y. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106720 · Cited by 18
Gouda, N. A., & Cho, J. (2022) · Antioxidants · doi:10.3390/antiox11101940 · Cited by 19
Metabolic Dysfunction in Parkinson’s Disease: Unraveling the Glucose–Lipid Connection
Sian‐Hülsmann, J., Riederer, P. F., & Michel, T. M. (2024) · Biomedicines · doi:10.3390/biomedicines12122841 · Cited by 20
Noreen, Z., Loffredo, C. A., Bhatti, A., Simhadri, J. J., Nunlee‐Bland, G., Nnanabu, T., John, P. C. L., Khan, J. S., & Ghosh, S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17165866 · Cited by 18
Grammatikopoulou, M. G., Tousinas, G., Balodimou, C., Anastasilakis, D. A., Gkiouras, K., Dardiotis, E., Evangeliou, A., Bogdanos, D. P., & Goulis, D. G. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.06.001 · Cited by 18
Ntetsika, T., Catrina, S., & Markaki, I. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01910 · Cited by 20
Mechanism and recent updates on insulin-related disorders
Kumar, S., Senapati, S., Bhattacharya, N., Bhattacharya, A., Maurya, S. K., Husain, H., Bhatti, J. S., & Pandey, A. K. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i25.5840 · Cited by 20
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 19
Dierssen, M., & Barone, E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.730378 · Cited by 16
Chan, L., Hsu, W., Chen, K., Wang, W., Hung, Y.-C., & Hong, C. (2023) · In Vivo · doi:10.21873/invivo.13300 · Cited by 16
Self-citationThe Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 18
Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila
Sanz, F., Solana‐Manrique, C., Lilao‐Garzón, J., Brito‐Casillas, Y., Muñoz‐Descalzo, S., & Paricio, N. (2022) · The FASEB Journal · doi:10.1096/fj.202200286r · Cited by 19
What Dietary Vitamins and Minerals Might Be Protective against Parkinson’s Disease?
Alizadeh, M., Kheirouri, S., & Keramati, M. (2023) · Brain Sciences · doi:10.3390/brainsci13071119 · Cited by 14
Sohail, M. U., Batool, R. M., Aamir, J., Saad, M., Aisha, E., Jain, H., Arshad, M. S., & Ahmed, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112239 · Cited by 14
PLK2 disrupts autophagic flux to promote SNCA/α-synuclein pathology
Zhang, C., Huang, Z.-P., Huang, X., Ma, Y., Cao, Y., Zhang, Z., Wang, R., Ren, H., Zheng, L. T., Liu, C.-F., et al. (2025) · Autophagy · doi:10.1080/15548627.2024.2448914 · Cited by 15
Imai, M., Kawakami, F., Kubo, M., Kanzaki, M., Maruyama, H., Kawashima, R., Maekawa, T., Kurosaki, Y., Kojima, F., & Ichikawa, T. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00377 · Cited by 10
He, P., Gao, Y. Y., Lyu, F., Chen, J. N., Zhang, Y. H., Nie, K., Zhang, Q. X., Huang, R., Duan, Q. R., Guo, M., et al. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/8548380 · Cited by 15
Li, F., Luo, Q., Guo, T., Zhou, S., Cheng, Z., Pan, H., & Tu, J. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2561789 · Cited by 17
Prebiotics and probiotics and Parkinson's disease
Amani, R., & Mehrabani, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90052-2.00034-2 · Cited by 9
Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson’s Disease and Frailty
Montanari, M., Mercuri, N. B., & Martella, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010122 · Cited by 13
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 14
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
Asadinejad, H., Taherkhani, S., Golboos, S. M., Azizi, Y., & Mohammadkhanizadeh, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05457-5 · Cited by 11
Tan, S., Chi, H., Pin, W., Zhao, R., Zhang, Q., Gao, Z., Xue, H., Tang, Q., & Li, G. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05436-4 · Cited by 12
Luo, J., Xu, H., Su, C., Dong, W., Xiao, M., Xiao, N., Jia, Y., & Xue, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202402793r · Cited by 8
Harpaz, K. A., Pollock-Gagolashvili, M., & Miller, Y. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00445 · Cited by 8
Hu, W., Zhang, Y., & Liu, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1621658 · Cited by 7
The Interplay of Stress, Inflammation, and Metabolic Factors in the Course of Parkinson’s Disease
Shaul, T. B., Frenkel, D., & Gurevich, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212409 · Cited by 8
Guo, P., Lu, Q., Ye, X., Martínez, M., López-Torres, B., Martínez, M., Martínez‐Larrañaga, M., Wang, X., Anadón, A., & Arés, I. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177750 · Cited by 8
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Cross Talks between CNS and CVS Diseases: An Alliance to Annihilate
Chib, S., Devi, S., Chalotra, R., Mittal, N., Singh, T. G., Kumar, P., & Singh, R. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x278550240221112636 · Cited by 7
Frailty and Parkinson’s disease: the role of diabetes mellitus
Komici, K., Pansini, A., Bencivenga, L., Rengo, G., Pagano, G., & Guerra, G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1377975 · Cited by 6
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
Duţă, C., Muscurel, C., Dogaru, C. B., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041516 · Cited by 8
Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review
Xie, Z., Liao, C., Shu, Y., Liu, Y., & Bian, S. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1381612828666220603124115 · Cited by 6
Li, W., Gao, B., Du, W. D., Jiang, Y., Yang, J., Hu, R., Liu, Y., Liu, N., Zhang, Y., Song, Q., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.975390 · Cited by 6
Šipošová, K., Petrenko, V. I., Garcarova, I., Sedláková, D., Almásy, L., Kyzyma, O. A., Kriechbaum, M., & Musatov, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.955282 · Cited by 7
Han, Z., Zhu, Y., Xia, Z., Deng, Q., He, H., Yin, Q., Zhang, H., Yuan, M., Yang, C., Tian, G., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-024-00859-z · Cited by 6
Hemedan, A. A., Satagopam, V., Schneider, R., & Ostaszewski, M. (2024) · iScience · doi:10.1016/j.isci.2024.110956 · Cited by 8
Samborska-Ćwik, J., Szlufik, S., Migda, B., Marszałek, A., & Koziorowski, D. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0060 · Cited by 7
Zeidan, O., Jaragh, N., Tama, M., Alkhalifa, M., Alqayem, M., & Butler, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168078 · Cited by 7
Shafiee, A., Akhlaghi, A., Ellstrom, A., Mohammadi, S. O., Shafiee, A., & Sathyamoorthy, M. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s539967 · Cited by 6
Relationship between Parkinson's disease and diabetes mellitus: Evidence from the bench to bedside
Peng, Y., Lin, L.-Y., Wu, S.-L., Kang, X.-H., Jiang, D., Yao, S., & Du, M. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108109 · Cited by 5
Shlapa, Y., Šipošová, K., Sarnatskaya, V. V., Drajnova, M., Silvestre‐Albero, J., Lykhova, O., Maraloiu, V., Solopan, S., Molčan, M., Musatov, A., et al. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00912 · Cited by 5
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Chen, B., Jen, C.-T., Wang, C., & Pan, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091200 · Cited by 6
Xiang, M., Cao, S.-Y., Sun, X.-H., Hu, J.-W., Lv, M., Li, J., & Li, W. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00573-1 · Cited by 3
Sucralose Targets the Insulin Signaling Pathway in the SH-SY5Y Neuroblastoma Cell Line
Čović, M., Zjalić, M., Mihajlović, L., Pap, M., Wagner, J., Mandić, D., Debeljak, Ž., & Heffer, M. (2023) · Metabolites · doi:10.3390/metabo13070817 · Cited by 3
Waheed, I., Sikandri, T., Zaheen, S., Khakwani, M. M. A. K., An, Z., Liu, T., Zhu, C., & Wei, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00819 · Cited by 3
Sun, M., Yin, P., Chen, S., & Wang, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00293 · Cited by 3
Bioinformatics analysis of potential key genes and mechanisms in type 2 diabetes mellitusPreprint
Vastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.28.437386 · Cited by 3
Unraveling the molecular crossroads: T2DM and Parkinson’s disease interactions
Liu, T., KONG, X., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.056272 · Cited by 3
Metadata
- Authors
- Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
- Taipei Medical University Hospital (TW)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Hong, Chien-Tai
- Bamodu, Oluwaseun
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-03-17
- Volume
- 9
- Issue
- 3
- Pages
- 740
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7140619
- OpenAlex
- W3011296966
- Cited by
- 133
- References
- 55
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 24 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 6
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Taipei Medical University Repository (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (105-2314-B-038-017, 106- 2314-B-038-023 MY3)
- Taipei Medical University (TMU105-AE1-B30)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- insulin resistance, Parkinson's disease, alpha-synuclein, PLK2, mitochondrial dysfunction, reactive oxygen species, dopaminergic neurons, PGC-1α, diabetes mellitus, neurodegeneration
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Male, Mice, Inbred C57BL, Mitochondria, Models, Biological, Parkinson Disease, Phosphoserine, Tyrosine 3-Monooxygenase, Signal Transduction, Genome, Human, Protein Serine-Threonine Kinases, Reactive Oxygen Species, Disease Progression, alpha-Synuclein, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.